Remsima 100 mg/vial Powder for concentrate for solution for infusion.
PDF Leaflet Revision Date: 20 December 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Dosage (summary)
Rheumatoid arthritis: 3 mg/kg IV at weeks 0, 2, 6, then every 8 weeks. Other indications: 5 mg/kg IV at weeks 0, 2, 6, then every 6-8 weeks.
Special Populations
- Elderly
- Paediatric patients
Pregnancy & Breastfeeding
Use contraception during treatment; avoid live vaccines in infants exposed in utero.
Key Drug Interactions
- Methotrexate may reduce antibody formation
- Avoid live vaccines
Contraindications
- Hypersensitivity to infliximab
- Active tuberculosis
- Severe infections
- Moderate to severe heart failure
Common side effects
- Upper respiratory tract infection
- Infusion reactions
- Headache
- Nausea
Counselling Points
- Monitor for signs of infection
- Report any allergic reactions
- Avoid live vaccines during treatment
Serious warnings
- Risk of serious infections
- Potential for malignancies
- Heart failure exacerbation
Important Disclaimer
The Remsima 100 mg/vial Powder for concentrate for solution for infusion. professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
